Mablink focuses its efforts on cancers with high unmet medical needs and, to demonstrate the high potential of its proprietary PSARlink™ technology, the first ADCs are addressing molecular targets for which ADCs have already shown clinical promise.
Mablink is currently developing three ADC programs:
Discovery
Preclinical
Phase I
Phase II
Disc.
Precl.
Ph. I
Ph. II
MBK-101
Acute Myeloid leukemia
Preclinical
MBK-102
Multiple Myeloma
Preclinical
MBK-103
Solid Tumors
Preclinical